|
|
| | Vatalanib Dihydrochloride Basic information |
| | Vatalanib Dihydrochloride Chemical Properties |
| Melting point | 268-2700C | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | Soluble in DMSO (up to 20 mg/ml with warming) or in Water (up to 100 mg/ml) | | form | solid | | color | White or off-white | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. | | CAS DataBase Reference | 212141-51-0 |
| | Vatalanib Dihydrochloride Usage And Synthesis |
| Description | Vatalanib is an antagonist of the VEGF receptors, inhibiting the receptor tyrosine kinase activities of VEGFR1 (Flt1), VEGFR2 (KDR), and VEGFR3 (Flt4) with IC50 values of 77, 37, and 190 nM, respectively. It less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on a large panel of additional kinases. Vatalanib completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice, suggesting its use in diabetic retinopathy and other diseases featuring aberrant vascular development. | | Chemical Properties | White to Off-White Crystalline Powder | | Uses | Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Antineoplastic. | | Uses | Vatalanib (PTK787) is an inhibitor of VEGFR2/KDR, Flt-1 and c-Kit with IC50 of 37 nM, 77 nM and 730 nM, respectively. | | References | 1) Wood?et al. (2000),?PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration;? Cancer Res.,?60?2178
2) Lin?et al. (2002),?The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in bone marrow microenvironment;? Cancer Res.,?62?5019 |
| | Vatalanib Dihydrochloride Preparation Products And Raw materials |
|